Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

NCT01899859 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Alcoholic Steatohepatitis (NASH)

Interventions

DRUG: GR-MD-02
DRUG: Placebo

Sponsor

Galectin Therapeutics Inc.